Literature DB >> 7235124

Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro.

J D Berman, F A Neva.   

Abstract

Leishmania tropica, a cause of cutaneous leishmaniasis, multiplied more rapidly within human macrophages in vitro at 35 degrees C than at 37 degree C, and was almost completely eliminated at 39 degrees C. In contrast, Leishmania donovani, the cause of the visceral leishmaniasis, multiplied equally well at 35 degrees C and at 37 degrees C,, and was only 40% eliminated at 39 degrees C. This in vitro study suggests that the localization of the two strains to cooler and warmer regions of the body, respectively, is at least partially explained by the inherent temperature sensitivity of the parasite-macrophage unit. The striking elimination of this strain of L. tropica within macrophages at 39 degrees C may make this model suitable for predicting the clinical response of cutaneous strains to heat therapy.

Entities:  

Mesh:

Year:  1981        PMID: 7235124     DOI: 10.4269/ajtmh.1981.30.318

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  22 in total

Review 1.  The genetics of Leishmania virulence.

Authors:  Eugenia Bifeld; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

Review 2.  Biochemistry of the Leishmania species.

Authors:  R H Glew; A K Saha; S Das; A T Remaley
Journal:  Microbiol Rev       Date:  1988-12

Review 3.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-11-17

4.  Efficacy, Safety and Cost-Effectiveness of Thermotherapy in the Treatment of Leishmania donovani-Induced Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial.

Authors:  Wardha F Refai; Nayani P Madarasingha; Buthsiri Sumanasena; Sudath Weerasingha; Amala De Silva; Rohini Fernandopulle; Abhay R Satoskar; Nadira D Karunaweera
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

Review 5.  Fever and the heat shock response: distinct, partially overlapping processes.

Authors:  J D Hasday; I S Singh
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

6.  Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.

Authors:  Olga Fernández; Yira Diaz-Toro; Liliana Valderrama; Clemencia Ovalle; Mabel Valderrama; Harry Castillo; Mauricio Perez; Nancy Gore Saravia
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

7.  A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection.

Authors:  Naomi E Aronson; Glenn W Wortmann; William R Byrne; Robin S Howard; Wendy B Bernstein; Mary A Marovich; Mark E Polhemus; In-Kyu Yoon; Kelly A Hummer; Robert A Gasser; Charles N Oster; Paul M Benson
Journal:  PLoS Negl Trop Dis       Date:  2010-03-09

Review 8.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-12-01

9.  Site-specific immunity to Leishmania major in SWR mice: the site of infection influences susceptibility and expression of the antileishmanial immune response.

Authors:  G S Nabors; J P Farrell
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

10.  Successful treatment of canine cutaneous leishmaniasis using radio-frequency induced heat (RFH) therapy.

Authors:  Anil A Ahuja; Ram A Bumb; Rajesh D Mehta; Neha Prasad; Ram K Tanwar; Abhay R Satoskar
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.